These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 34091114)
1. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy. Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933 [TBL] [Abstract][Full Text] [Related]
3. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095 [TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490 [TBL] [Abstract][Full Text] [Related]
6. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518 [TBL] [Abstract][Full Text] [Related]
7. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291 [TBL] [Abstract][Full Text] [Related]
8. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647 [TBL] [Abstract][Full Text] [Related]
10. Lomustine and Bevacizumab in Progressive Glioblastoma. Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164 [TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
13. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis. Guo G; Zhang Z; Zhang J; Wang D; Xu S; Liu G; Gao Y; Mei J; Yan Z; Zhao R; Wang M; Li T; Bu X Cancer Immunol Immunother; 2024 Aug; 73(10):193. PubMed ID: 39105794 [TBL] [Abstract][Full Text] [Related]
14. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. Urup T; Dahlrot RH; Grunnet K; Christensen IJ; Michaelsen SR; Toft A; Larsen VA; Broholm H; Kosteljanetz M; Hansen S; Poulsen HS; Lassen U Acta Oncol; 2016; 55(4):418-22. PubMed ID: 26828563 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811 [TBL] [Abstract][Full Text] [Related]
16. Aging- and Tumor-Mediated Increase in CD8 Huff WX; Bam M; Shireman JM; Kwon JH; Song L; Newman S; Cohen-Gadol AA; Shapiro S; Jones T; Fulton K; Liu S; Tanaka H; Liu Y; Wan J; Dey M Immunohorizons; 2021 Jun; 5(6):395-409. PubMed ID: 34103370 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589 [TBL] [Abstract][Full Text] [Related]
18. Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years. Mukherjee S; Wood J; Liaquat I; Stapleton SR; Martin AJ Clin Neurol Neurosurg; 2020 Jan; 188():105568. PubMed ID: 31739155 [TBL] [Abstract][Full Text] [Related]
19. Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab. Wang D; Zhang J; Bu C; Liu G; Guo G; Zhang Z; Lv G; Sheng Z; Yan Z; Gao Y; Wang M; Liu G; Zhao R; Li T; Ma C; Bu X J Cancer Res Clin Oncol; 2024 Oct; 150(10):466. PubMed ID: 39422764 [TBL] [Abstract][Full Text] [Related]
20. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]